

Supplemental Table 3. Included papers in this review (n=48)

Study author & year	Participants (n)	Study type	RVO type	Drug regimen	Study outcomes	Conclusions
(Abdallah et al., 2019)	9	Retrospective case series	Separate CRVO & BRVO data	Dexamethasone	BCVA & CRT at 3 years	No significant vision gains with dexamethasone.
(Bajric & Bakri, 2016)	5	Retrospective case series	CRVO only	Combination	BCVA & CRT at 2, 3 & 4 years	BCVA & CRT improvement maintained at four years.
(Blanc et al., 2018)	66	Retrospective case series	Mixed	Dexamethasone & combination	BCVA & CRT at 2 & 3 years	Dexamethasone effective at 3 years.
(Blin et al., 2018)	301	Cohort	Separate CRVO & BRVO data	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab effective at 2 years.
(Brown et al., 2014)	15	Cohort	CRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab improved vision.
(Busch et al., 2019)	155	Retrospective case series	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2 & 3 years	Early treatment improved final outcomes.
(Calugaru & Calugaru, 2015)	57	Cohort	CRVO only	Bevacizumab	BCVA & CRT at 3 years	Bevacizumab improved vision at 3 years.
(Campochiaro et al., 2010a)	40	RCT	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2 years	Long term visual improvement with anti-VEGF.
(Campochiaro et al., 2014)	66	Cohort	Separate CRVO & BRVO data	Ranibizumab	BCVA & CRT at 2, 3 & 4 years	Ranibizumab improves long term visual outcomes.
(Chatziralli et al., 2017)	15	Retrospective case series	CRVO only	Combination	BCVA & CRT at 2 years	Anti-VEGF is effective for MO due to RVO.
(Chatziralli et al., 2018)	54	Retrospective case series	Separate CRVO & BRVO data	Ranibizumab	BCVA & CRT at 2, 3 & 4 years	Ranibizumab is effective long term.
(Chittajallu & Prakash, 2018)	101	Retrospective case series	BRVO only	Ranibizumab	BCVA at 2 years	Long term ranibizumab is effective.
(Costa et al., 2021)	208	Retrospective case series	Mixed	Dexamethasone & combination	BCVA & CRT at 3 years	Intravitreal treatment improved long term outcomes.
(Farinha et al., 2015)	32	Retrospective case series	Separate CRVO & BRVO data	Ranibizumab	BCVA & CRT at 2 & 3 years	Ranibizumab was satisfactory long term.
(Gale et al., 2020)	4879	Retrospective case series	CRVO only	Ranibizumab, dexamethasone & combination	BCVA at 2 & 3 years	Better visual outcomes with ranibizumab than other treatments.
(Guichard et al., 2018)	76	Retrospective case series	Mixed	Ranibizumab	BCVA & CRT at 2 years	Treat & extend superior to PRN for MO due to RVO.
(Heier et al., 2012)	203	RCT	Separate CRVO & BRVO data	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab is safe & effective.
(Heier et al., 2014)	114	RCT	CRVO only	Aflibercept	BCVA & CRT at 2 years	Anatomical improvements reduced between weeks 52 & 100.
(Hikichi et al., 2014)	89	Cohort	BRVO only	Bevacizumab	BCVA & CRT at 2 years	Bevacizumab is beneficial at 2 years
(Horner et al., 2020)	54	Cohort	Separate CRVO & BRVO data	Ranibizumab & combination	BCVA & CRT at 2 & 3 years	Combination therapy effective for MO due to RVO.
(Hosogi et al., 2019)	32	Retrospective case series	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab effective for BRVO patients.
(Hykin et al., 2019)	463	RCT	CRVO only	Ranibizumab, aflibercept & bevacizumab	BCVA & CRT at 2 years	Aflibercept was non-inferior to ranibizumab.
(Iftikhar et al., 2019)	90	Prospective case series	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2, 3, 4 & 5 years	Sustained anti-VEGF improved visual & anatomical outcomes.
(Inagaki et al., 2019)	20	Cohort	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab improved vision at 2 years.

Study author & year	Participants (n)	Study type	RVO type	Drug regimen	Study outcomes	Conclusions
(Khurana et al., 2019)	16	Cohort	CRVO only	Aflibercept	BCVA & CRT at 2 years	Aflibercept provided improvement at 2 years
(Korobelnik et al., 2016)	375	Cohort	Separate CRVO & BRVO data	Dexamethasone	BCVA & CRT at 2 years	Dexamethasone implant is safe
(Larsen et al., 2018)	357	Cohort	CRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab is effective at 2 years
(Lee, Jung & Sohn, 2014)	453	Cohort	BRVO only	Triamcinolone, bevacizumab & combination	BCVA at 2 years	Anti-VEGF provides improved BCVA at 2 years.
(Lida-Miwa et al., 2019)	58	Prospective case series	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Neovascular changes present in BRVO treated with ranibizumab.
(Lo et al., 2020)	214	Retrospective case series	Mixed	Combination	BCVA & CRT at 2 years	Early BCVA & CRT improvements may predict long-term outcomes.
(Lo et al., 2021)	214	Retrospective case series	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2 years	Early anatomic response increases chance of treatment cessation.
(Loukiano et al., 2016)	33	Cohort	Separate CRVO & BRVO data	Bevacizumab	BCVA & CRT at 2 years	Bevacizumab provides long term BCVA improvement.
(Maggio et al., 2020)	223	Cohort	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2, 3, 4 & 5 years	Ranibizumab & dexamethasone effective long term.
(Mansour et al., 2018)	10	Cohort	Mixed	Aflibercept	BCVA at 2 years	BCVA improves over 2 years with aflibercept.
(McAllister et al., 2018)	29	RCT	CRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab effective in CRVO patients.
(Ozkaya, Tarakcioglu & Tanir, 2018)	174	Retrospective case series	BRVO only	Ranibizumab & dexamethasone	BCVA & CRT at 2 years	Ranibizumab & dexamethasone effective in BRVO.
(Risard et al., 2011)	20	Cohort	CRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab improves visual & anatomical outcomes.
(Sakanishi et al., 2021)	40	Cohort	BRVO only	Aflibercept	BCVA & CRT at 2 years	Aflibercept effective at 2 years for BRVO .
(Scott et al., 2011)	389	RCT	Separate CRVO & BRVO data	Combination	BCVA & CRT at 2 years	Younger age predictive of higher BCVA.
(Sen et al., 2021)	267	RCT	CRVO only	Combination	BCVA at 2 years	Higher baseline BCVA was predictive of better BCVA outcomes.
(Sophie et al., 2013)	21	Retrospective case series	Separate CRVO & BRVO data	Ranibizumab	BCVA at 2 years	Infrequent ranibizumab not sufficient to treat MO due to RVO.
(Sophie et al., 2019)	205	RCT	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Perfusion maintenance crucial for good outcomes in CRVO.
(Spooner et al., 2019)	68	Retrospective case series	Separate CRVO & BRVO data	Combination	BCVA & CRT at 5 years	Anti-VEGF achieved good long term outcomes for RVO.
(Stredova et al., 2019)	39	Cohort	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Ranibizumab improved long term outcomes for BRVO.
(Tadayoni et al., 2017)	183	RCT	BRVO only	Ranibizumab	BCVA & CRT at 2 years	Long term efficacy & safety of ranibizumab proven.
(Tsagakataki et al., 2015)	35	Retrospective case series	BRVO only	Bevacizumab	BCVA & CRT at 2 years	Bevacizumab provided resolution of MO in one third of patients.
(Volkman et al., 2020)	16	Cohort	Mixed	Combination	BCVA at 2 years	BCVA improves with anti-VEGF.
(Wu et al., 2009)	63	Cohort	BRVO only	Bevacizumab	BCVA & CRT at 2 years	Bevacizumab is effective at 2 years.